Clinical Trials Sponsored by Dentsply Sirona Inc.

Total 223 results

Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
EMD Serono Research & Development Institute, Inc.

Recruiting

The MS-LINK™ Outcomes Study

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
EMD Serono Research & Development Institute, Inc.

Recruiting

Next-Gen MS: Feed-forward PRO Data for MS Research

Multiple Sclerosis (MS)

United States
EMD Serono Research & Development Institute, Inc.

Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Carcinoma, Merkel Cell

United States, Spain, Australia, Italy, Germany, France, Japan
EMD Serono Research & Development Institute, Inc.

Completed

CLARITY Extension Study

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Bulgaria, France, Italy, Russian Federation, Turkey, United Kingdom, Estonia, Germany, Latvia, Lithuania, Poland, Austria, Brazil, Canada, Finland, Portugal, Greece, Serbia, Denmark, Ukraine, Saudi Arabia, Lebanon and more
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
Corona Doctors Medical Clinics, Inc.

Unknown

Treatment of Chronic Migraine Headaches. (Migraine)

Migraine Disorders | Chronic Migraine Without Aura, Intractable | Migraine With Typical Aura

United States
Sona Nanotech Inc

Terminated

Performance Study of SONA Saliva C-19 Rapid Test

Covid19 | Corona Virus Infection | Sars-CoV-2 Infection

Canada
Criterium, Inc.
EMD Serono Research & Development Institute, Inc.

Terminated

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Advanced Non-Small Cell Lung Cancer With MET Mutations

United States
Columbia University
EMD Serono; Genentech, Inc.

Terminated

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

Growth Hormone Deficiency | Pituitary Tumor

United States
Viron Therapeutics Inc
Vion Pharmaceuticals

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
EuroPharma, Inc.
Simon Khechinashvili University

Terminated

Echinacea Angustifolia (AnxioCalm) in Anxiety

Generalized Anxiety Disorder

Georgia
Promontory Therapeutics Inc.
Pfizer; EMD Serono

Completed

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1)

Non-Small Cell Lung Cancer (NSCLC)

United States, Switzerland
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501)

Advanced Solid Tumor

United States, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Colorectal Cancer

United States, Japan, Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

Cancer

United States, Israel, Spain, Finland, France, Belgium, Netherlands, United Kingdom, Canada, Italy, Germany, Sweden, Austria, Czechia, Portugal
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

Advanced Solid Tumors

Canada, United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

Multiple Myeloma

United States, France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

Coronavirus Disease 2019

United States, Brazil, Philippines
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Evobrutinib in Participants With RMS

Relapsing-remitting Multiple Sclerosis

United States, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Metastatic or Locally Advanced Unresectable Solid Tumors

United States
Beyond Air Inc.
Soroka University Medical Center

Completed

Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis

Bronchiolitis

Israel
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Head and Neck Cancer

Taiwan, United States, Korea, Republic of, Spain, Belgium, Israel
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Portugal, Romania, Spain, Switzerland, Netherlands, P... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Central Nervous System Tumors

Korea, Republic of, United States, Canada, Germany, France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, China, Spain, Japan, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Bintrafusp Alfa Program Rollover Study

Cancer | Lung Cancer

Korea, Republic of, Spain, Germany, Japan, Taiwan, China, Italy, United States, Belgium, Russian Federation, Turkey, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Non-small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, China, Hong Kong, France, Russian Federation, Netherlands, Japan, Spain, Italy, Belgium, Vietnam, Malaysia, Thailand, Germany, Singapore
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Multiple Sclerosis (MS)

United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M1231 in Participants With Solid Tumors

Esophageal Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumors

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib Hepatic Impairment Trial

Hepatic Impairment

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Advanced Solid Tumors

United States, Germany, Norway, Netherlands, Belgium, Denmark, Sweden, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Phase II Study of M2951 in SLE

Systemic Lupus Erythematosus

Philippines, United States, Korea, Republic of, Malaysia, Taiwan, Germany, Italy, Poland, Mexico, Bulgaria, Peru, Argentina, Chile, Colombia, Japan, Mauritius, Romania, Russian Federation, South Africa
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Ovarian Cancer

Belgium, United States, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Ukraine, United States, Czechia, Poland, Argentina, Mexico, South Africa, Chile, Bulgaria, Colombia, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M6620 First in Human Study

Advanced Solid Tumor

United States, United Kingdom

Clinical Trials Sponsored by Dentsply Sirona Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations